共 36 条
[1]
Ceccarelli S(2019)Notch3 targeting: a novel weapon against ovarian cancer stem cells Stem Cells Int 2019 6264931-2313
[2]
Jiang X(2019)PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms J Cell Mol Med 23 2303-5171
[3]
Fields EC(2017)Radiation treatment in women with ovarian cancer: past, present, and future Front Oncol 7 177-7279
[4]
Marques MP(2015)A molecular view of cisplatin's mode of action: interplay with DNA bases and acquired resistance Phys Chem Chem Phys 17 5155-2617
[5]
Siddik ZH(2003)Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 7265-2192
[6]
Zaman GJR(2017)TTK inhibitors as a targeted therapy for CTNNB1 (β-catenin) mutant cancers Mol Cancer Ther 16 2609-1331
[7]
Maia AR(2015)Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model Ann Oncol 26 2180-1792
[8]
Tannous BA(2013)Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs J Natl Cancer Inst 105 1322-1316
[9]
Housman G(2014)Drug resistance in cancer: an overview Cancers (Basel) 6 1769-2811
[10]
Komatsu M(2000)Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance Cancer Res 60 1312-1302